A dose-ranging study of the pharmacodynamic effects of BMS-562086 [pexacerfont] on gastrointestinal transit in women with diarrhea-predominant irritable bowel syndrome

Trial Profile

A dose-ranging study of the pharmacodynamic effects of BMS-562086 [pexacerfont] on gastrointestinal transit in women with diarrhea-predominant irritable bowel syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 17 May 2008

At a glance

  • Drugs Pexacerfont (Primary)
  • Indications Irritable bowel syndrome
  • Focus Pharmacodynamics
  • Most Recent Events

    • 20 Mar 2008 Status changed from in progress to completed, in accordance with clinicaltrials.gov.
    • 10 Sep 2007 Status changed from recruiting to in progress.
    • 09 Jan 2007 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top